Literature DB >> 16257559

The importance of standardisation of laboratory evaluations in HIV vaccine trials.

Frances Gotch1, Harvey Holmes, Nesrina Imami.   

Abstract

It is important to evaluate HIV-1-specific immunological responses elicited by therapeutic or prophylactic vaccines using precise, standardised assays, so that the immunogenicity and putative efficacy of candidate vaccines may be compared. Different well-validated assays must be used to quantitate specific responses, to determine which particular strategies may be efficacious.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16257559     DOI： 10.1016/j.micinf.2005.07.020

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  6 in total

1.  Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

Authors:  Eric Sandström; Charlotta Nilsson; Bo Hejdeman; Andreas Bråve; Göran Bratt; Merlin Robb; Josephine Cox; Thomas Vancott; Mary Marovich; Richard Stout; Said Aboud; Muhammad Bakari; Kisali Pallangyo; Karl Ljungberg; Bernard Moss; Patricia Earl; Nelson Michael; Deborah Birx; Fred Mhalu; Britta Wahren; Gunnel Biberfeld
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

2.  The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.

Authors:  Carmen Elena Gómez; José Luis Nájera; Beatriz Perdiguero; Juan García-Arriaza; Carlos Oscar S Sorzano; Victoria Jiménez; Rubén González-Sanz; José Luis Jiménez; María Angeles Muñoz-Fernández; Juan Carlos López Bernaldo de Quirós; Alberto C Guardo; Felipe García; José M Gatell; Montserrat Plana; Mariano Esteban
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

Review 3.  The potential role of biomarkers in HIV preventive vaccine trials.

Authors:  Ellen Maclachlan; Kenneth H Mayer; Ruanne Barnabas; Jorge Sanchez; Beryl Koblin; Ann Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

4.  Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 August 2005, London, UK.

Authors:  Anjeanette Roberts; John Wood; Kanta Subbarao; Morag Ferguson; David Wood; Thomas Cherian
Journal:  Vaccine       Date:  2006-07-18       Impact factor: 3.641

5.  Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.

Authors:  Nesrina Imami; Samantha J Westrop; Nathali Grageda; Anna A Herasimtschuk
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

6.  Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time.

Authors:  Ingrid M M Schellens; José A M Borghans; Christine A Jansen; Iris M De Cuyper; Ronald B Geskus; Debbie van Baarle; Frank Miedema
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.